KR20230069947A - Sppl2a 억제제로서의 화합물 및 조성물 - Google Patents
Sppl2a 억제제로서의 화합물 및 조성물 Download PDFInfo
- Publication number
- KR20230069947A KR20230069947A KR1020237011546A KR20237011546A KR20230069947A KR 20230069947 A KR20230069947 A KR 20230069947A KR 1020237011546 A KR1020237011546 A KR 1020237011546A KR 20237011546 A KR20237011546 A KR 20237011546A KR 20230069947 A KR20230069947 A KR 20230069947A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- benzo
- oxo
- pyrazolo
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| US63/079,604 | 2020-09-17 | ||
| PCT/IB2021/058398 WO2022058902A1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230069947A true KR20230069947A (ko) | 2023-05-19 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237011546A Pending KR20230069947A (ko) | 2020-09-17 | 2021-09-15 | Sppl2a 억제제로서의 화합물 및 조성물 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (https=) |
| EP (2) | EP4578451A3 (https=) |
| JP (2) | JP7771172B2 (https=) |
| KR (1) | KR20230069947A (https=) |
| AU (1) | AU2021342783A1 (https=) |
| CA (1) | CA3192763A1 (https=) |
| CL (2) | CL2023000728A1 (https=) |
| CO (1) | CO2023004646A2 (https=) |
| CR (1) | CR20230142A (https=) |
| DK (1) | DK4214210T3 (https=) |
| DO (1) | DOP2023000055A (https=) |
| EC (1) | ECSP23027092A (https=) |
| ES (1) | ES3028668T3 (https=) |
| FI (1) | FI4214210T3 (https=) |
| GE (2) | GEAP202516217A (https=) |
| HR (1) | HRP20250562T1 (https=) |
| HU (1) | HUE071569T2 (https=) |
| IL (1) | IL300953B1 (https=) |
| JO (1) | JOP20230044A1 (https=) |
| LT (1) | LT4214210T (https=) |
| MA (1) | MA61557B1 (https=) |
| MD (1) | MD4214210T2 (https=) |
| MX (1) | MX2023003122A (https=) |
| PE (1) | PE20231099A1 (https=) |
| PL (1) | PL4214210T3 (https=) |
| PT (1) | PT4214210T (https=) |
| RS (1) | RS66874B1 (https=) |
| SI (1) | SI4214210T1 (https=) |
| SM (1) | SMT202500216T1 (https=) |
| WO (1) | WO2022058902A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| US20250263416A1 (en) | 2024-02-15 | 2025-08-21 | Incyte Corporation | SPPL2a INHIBITORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| JP2008545780A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| WO2015160772A1 (en) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
-
2021
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/en active Pending
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 IL IL300953A patent/IL300953B1/en unknown
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/en active Active
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/en not_active Ceased
- 2021-09-15 CA CA3192763A patent/CA3192763A1/en active Pending
-
2023
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019203476B2 (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| JP2017504631A (ja) | 化合物 | |
| JP2010526145A (ja) | ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト | |
| JP2026041723A (ja) | Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物 | |
| JP2019031532A (ja) | Ｂａｃｅ１阻害剤 | |
| TW201706274A (zh) | 吡咯［２，３－ｄ］嘧啶基、吡咯［２，３－ｂ］吡基和吡咯［２，３－ｂ］吡啶基丙烯醯胺及其環氧化物 | |
| AU2012292036A1 (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| KR20220042132A (ko) | 2h-이미다졸 유도체 및 질환 치료에서 그의 용도 | |
| CA3120037A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| CA2980161A1 (en) | Heterocyclic compounds useful as inhibitors of tnf | |
| WO2021117759A1 (ja) | 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤 | |
| CN116615425B (zh) | 作为Sppl2a抑制剂的化合物和组合物 | |
| HK40128790A (en) | Compounds and compositions as sppl2a inhibitors | |
| CN119032083A (zh) | Malt1调节剂和其用途 | |
| CN118591536A (zh) | Irak4抑制剂 | |
| EA048012B1 (ru) | Соединения и композиции в качестве ингибиторов sppl2a | |
| US20250263416A1 (en) | SPPL2a INHIBITORS | |
| CA2952160A1 (en) | 2,2,2-trifluoroethyl-thiadiazines | |
| WO2025133915A1 (en) | Compounds which bind to pnpla3i148m and their use to treat liver diseases | |
| HK40008443A (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
| HK1230195A1 (en) | 2,2,2-trifluoroethyl-thiadiazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |